Biosimilars in IBD: Will it Benefit to Patients, Physicians or the Health Care System?

Author(s): Lorant Gonczi, Akos Ilias, Zsuzsanna Kurti, Peter L. Lakatos*.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 1 , 2019


Abstract:

The introduction of biological drugs has revolutionized the management of inflammatory bowel diseases (IBD), however, the increasing financial burden of biologicals on the health care system is alarming. Biosimilars are considered to be equivalent to the reference medicinal product (RMP) in terms of pharmacokinetic properties, clinical effectiveness and safety. CT-P13 infliximab was the first biosimilar to be approved by the regulatory authorities EMA and US FDA, and others are becoming increasingly available as patents expire on the RMP. Emerging data suggests that one-way switching from the RMP to an approved biosimilar is safe and acceptable, however data on multiple-switching, reversed switching, or cross-switching between biosimilars is scarce. Accumulating data on biosimilars led to an increased acceptance amongst physicians and their use can be expected to offer increased availability for patients, and also better control of economic sustainability. This review discusses the available data on clinical efficacy and safety of approved biosimilar agents, and assesses the current impact and future perspectives of biosimilars on the health care system.

Keywords: Crohn's disease, ulcerative colitis, biosimilars, infliximab, switch, cost-effectiveness.

[1]
van der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFa therapy: results from the COIN study. Gut 2014; Jan;. 63(1): 72-9.
[2]
Braun J, Kudrin A. Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health. Biologicals 2016; 44: 257-66.
[3]
U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation (CDER) and Center for Biologics Evaluation and Research (CBER) Scientific considerations in demonstrating biosimilarity to a reference product Guidance for industry 2018.April; [Accessed on July 2018]; Available from http://www.fda.gov/downloads/DrugsGuidanceCompliance RegulatoryInformation/Guidances/UCM291128.pdfb.
[4]
European Medicines Agency. Guideline on similar biological medicinal products 2014.[Accessed on July 2018]; updated 10/23/2014. Available from: http://www.ema.europa.eu/ docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf.
[5]
European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues Committee for Medicinal Products for Human Use (CHMP) 2009.[Accessed on July 2018]; http://www.ema.europa. eu/docs/en_GB/document_library/ Scientific_guideline/2009/09/WC500003953.pdf.
[6]
Bui LA, Hurst S, Finch GL, et al. Key considerations in the preclinical development of biosimilars. Drug Discov Today 2015; 20(Suppl. 1): 3-15.
[7]
Ben-Horin S, Vande Casteele N, Schreiber S, Lakatos PL. Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin Gastroenterol Hepatol 2016; 14(12): 1685-96.
[8]
Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 2014; 42: 177e83.
[9]
Cohen H, Beydoun D, Chien D, et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther 2017; 33(12): 2160-72.
[10]
European Medicines Agency.Assessment Report: Inflectra 2013.[Accessed on July 2018]; Available at: http://www.ema.europa.eu/ docs/ en_GB/document_library/EPAR_-_Public_assessment_ report/ human/002778/WC500151490.pdf.
[11]
INFLECTRA prescribing information [July 2018];2018 Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/ 125544s000lbl.pdf.
[12]
European Medicines Agency. Assessment Report: Flixabi 2016.[July 2018]; Available at: http://www.ema.europa.eu/ema/ index.jsp?curl=pages/medicines/human/medicines/004020/human_med_001980.jsp&mid=WC0b01ac058001d124.
[13]
Drugs@FDA: FDA Approved Drug Products.. Renflexis prescribing information [July 2018]; Available at: https://www.accessdata. fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761054.
[14]
European Medicines Agency. Assessment Report: Zessly 2018.[July 2018]; Available at: http://www.ema.europa.eu/ ema/index. jsp?curl=pages/medicines/human/medicines/004647/human_med_002260.jsp&mid=WC0b01ac058001d124.
[15]
U S Food and Drug Administration.. FDA press announcement_ Amjevita 2016 [July 2018]; Available at: https://www. fda.gov/ newsevents/newsroom/pressannouncements/ucm522243. htm.
[23]
Fiorino G, Manetti N, Armuzzi A, et al. The PROSIT-BIO cohort: A prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm Bowel Dis 2017; 23(2): 233-43.
[24]
Smits LJ, Derikx LA, de Jong DJ, et al. Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: A prospective observational cohort study. J Crohn’s Colitis 2016; 10(11): 1287-93.
[25]
Buer LC, Moum BA, Cvancarova M, Warren DJ, Medhus AW, Høivik ML. Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study. J Crohn’s Colitis 2017; 11(3): 297-304.
[26]
Razanskaite V, Bettey M, Downey L, et al. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme. J Crohn’s Colitis 2017; 11(6): 690-6.
[27]
Gonczi L, Gecse KB, Vegh Z, et al. Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort. Inflamm Bowel Dis 2017; 23(11): 1908-15.
[28]
Ye BD, Kim YH, Pesegova M, et al. Phase III randomized controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active crohn’s disease: 1-year maintenance and switching results. Gastroenterology 2018; 154(6)(Suppl. 1): S-167-8.
[29]
Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): A 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017; 389(10086): 2304-16.
[30]
Joergensen KK, Goll GL, Sexton J, et al. Long-Term Efficacy and Safety of CT-P13 after Switching from Originator Infliximab: Exploratory Subgroup Analyses in IBD in the Nor-Switch Extension Trial. Gastroenterology 2018; 154(6): S-168.
[31]
Fischer S, Klenske E, Schmitt H, et al. Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi ®) in inflammatory bowel disease patients. J Crohn’s Colitis 2018; 12(Suppl. 1): S416.
[32]
Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study. Ann Rheum Dis 2017; 76(10): 1679-87.
[33]
Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol 2017; 76(6): 1093-102.
[34]
Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. J Crohn’s Colitis 2017; 11(1): 26-34.
[35]
Ilias A, Szanto K, Gonczi L, et al. Non-Medical Mandatory Reversed and Back and Forth Switch Between Infliximab and its Biosimilar: Early Clinical Outcomes. Gastroenterology 2018; 154(6)(Suppl. 1): S-822.
[36]
van der Valk ME, Mangen MJ, Severs M, et al. Evolution of costs of inflammatory bowel disease over two years of follow-up. PLoS One 2016; 11(4): e0142481.
[37]
Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006; 131(3): 719-28.
[38]
Rovira J, Espin J, Garcia L. The impact of biosimilars’entry in the EU market. Andalusian Sch Pub Health 2011; 30: 1-83.
[39]
Severs M, Oldenburg B, van Bodegraven AA, Siersema PD, Mangen MJ. The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease. J Crohn’s Colitis 2017; 11(3): 289-96.
[40]
Brodszky V, Rencz F, Péntek M, Baji P, Lakatos PL, Gulácsi L. A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Rev Pharmacoecon Outcomes Res 2016; 16(1): 119-25.
[41]
Rencz F, Gulácsi L, Péntek M, et al. Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe. Expert Rev Pharmacoecon Outcomes Res 2017; 17(6): 597-606.
[42]
Baji P, Gulácsi L, Brodszky V, et al. Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe. United European Gastroenterol J 2018; 6(2): 310-21.
[43]
Jha A, Upton A, Dunlop WC, Akehurst R. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries. Adv Ther 2015; 32(8): 742-56.
[44]
An Hong J, Kudrin A. 5 year budget impact analysis of CT-P13 (Infliximab) for the treatment of Crohn’s Disease in UK, Italy and France. J Crohn’s Colitis 2015; 9(1): S144-5.
[45]
NICE The National Institute for Health and Care Excellence- Biosimilar medicines j Guidance and guidelines.Accessed: 13/12/2017.Available from: https://www.nice.org.uk/advice/ktt15/ chapter/evidence-context [Accessed July 2018].
[46]
GaBI Online - Switching approaches to biosimilars in Nordic countries. [ www.gabionline.net ] Mol, Belgium: Pro Pharma Communications International; [cited 2015 May 13]. Accessed: 13/12/2017.Available from: http://www.gabionline.net/Reports/ Switching-approaches-to-biosimilars-in-Nordiccountries [Accessed July 2018]
[47]
Positioning Statements on Physician-led Switching for Biosimilar Medicines e Memo Update June 2017. [Accessed: 20/12/2017] Available at: http://www.medicinesforeurope.com/wp-content/uploads/2017/03/M-Biosimilars-Overview-of-positions-on-physician-led-switching.pdf [Accessed July 2018].
[48]
Finnish Medicines Agency Fimea Are biosimilars interchangeable? https://www.fimea.fi/documents/542809/838272/29197_ Biosimilaarien_vaihtokelpoisuus_EN.pdf [Accessed July 2018].
[49]
2015.Position of Paul-Ehrlich-Institute regarding the use of biosimilars.Update December 2015.http://www.pei.de/ EN/ medicinalproducts/antibodies-immunoglobulins-fusion-proteins/monoclonalantibodies/biosimilars/position-pei-interchangebility-biosimilarscontent [Accessed July 2018]..
[50]
National Health Insurance Fund of Hungary Current standing regulations of infliximab treatment in IBD patients in Hungary Accessed: 2018.01.04. Available at: http://www.neak.gov.hu/felso_ menu/rolunk/kozerdeku_adatok/kozbeszerzesi_informaciok/kozbeszerzesi_eljarasok/2017_unios/infliximab [Accessed July 2018].
[51]
Regulatory Affairs Professionals Society: FDA Issues Long- Awaited Biosimilar Interchangeability Guidance. Accessed: 20/12/2017 Available at: http://www.raps.org/Regulatory-Focus/ News/2017/01/17/26624/FDA-Issues-Long-Awaited-Biosimilar-Interchangeability-Guidance [Accessed July 2018]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 1
Year: 2019
Page: [13 - 18]
Pages: 6
DOI: 10.2174/1381612825666190312112900
Price: $58

Article Metrics

PDF: 27
HTML: 9
EPUB: 1
PRC: 1

Special-new-year-discount